Live
Endpoints NewsLilly obesity meds Foundayo and Zepbound to gain CVS coverageBioPharma DiveGSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’Endpoints NewsFor wearables, it’s a GLP-1 worldBioPharma DiveCVS obesity drug deal puts Lilly on equal footing with NovoFierceBiotechIcon ends internal accounting investigation, finds it overstated revenue in prior yearsFierceBiotechFDA extends Beren’s rare disease review after info request, further stretching sagaBioWorldBreakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infectionsEndpoints NewsICON audit finds overstated revenue; Secretome and Psilera raise cashEndpoints News#ASCO26: After leaving Legend, Frank Fan is ready to showcase his next projectFierceBiotechHoth Therapeutics’ pivot to AI in space sees stock rocket after rebrandCellFarnesylation-driven KRAS phase separation promotes colon tumor growthCellStructural basis of Wnt signalosome extracellular complex assembly
FierceBiotech Apr 13, 2026

Regeneron rides into radiopharma via $2.1B biobucks pact with Australia’s Telix

Regeneron rides into radiopharma via $2.1B biobucks pact with Australia’s Telix

Original
Body unavailable. Use the original source.